Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) and mutation of the p53 are both commonly detected in human prostate cancer cells. We sought to investigate whether there is functional regulation of Stat3 by wild-type (wt) p53. Our results demonstrate that expression of wt p53 but not mutant p53 signi®cantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Expression of the p53 downstream target, p21
Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) and mutation of the p53 are both commonly detected in human prostate cancer cells. We sought to investigate whether there is functional regulation of Stat3 by wild-type (wt) p53. Our results demonstrate that expression of wt p53 but not mutant p53 signi®cantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Expression of the p53 downstream target, p21
WAF-1 , did not have any inhibitory eect on Stat3 phosphorylation. Wt p53 but not p21 induced dramatic apoptosis in these prostate cancer cells. Expression of wt p53 did not cause a reduction of phosphorylation-independent Stat3 protein and reduction of phosphorylation of three unrelated protein kinases, ERK1, ERK2 (ERK1/2), and AKT. Interestingly, p53-dependent apoptosis occurred in the presence of high levels of phosphorylated AKT and ERK1/2 in both DU145 and Tsu prostate cancer cells. Further, we evaluated a series of established human prostate, breast, and ovarian cancer cell lines and found that all cancer cell lines expressing constitutively active Stat3, only harbor mutated or deleted p53. One implication of these results is that the anti-proliferative activities of p53 may not be compatible with the constitutive Stat3 signal in cancer cells. Oncogene (2002) 21, 3082 ± 3088. DOI: 10.1038/sj/ onc/1205426
Keywords: p53; Stat3; prostate cancer; apoptosis STAT signaling pathways are activated in response to cytokines and growth factors (Zhong et al., 1994) . A growing number of tumor-derived cell lines as well as tumor specimens from human cancers are reported to express constitutively activated Stat proteins, very frequently Stat3 (Bowman et al., 2000) . For example, constitutive activation of Stat3 has been detected in prostate, breast, ovarian, head and neck and other cancers (Garcia et al., 1997; Bowman et al., 2000; Huang et al., 2000; Ni et al., 2000) . Stat3 has been classi®ed as an oncogene because the constitutively active Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice (Bromberg et al., 1999) . Stat3 activation may not only provide a growth advantage, allowing accumulation of tumor cells, but also confer resistance to conventional therapies that rely on apoptotic machinery to eliminate tumor cells. The events downstream from constitutively active Stat3 that promote tumorigenesis are unclear but could include deregulation of cell cycle progression and/or providing protection against apoptosis. For example, constitutive activation of Stat3 signaling can confer resistance to apoptosis in human myeloma cells and in ®broblasts (Shen et al., 2001) . Constitutive activation of Stat3 can also upregulate the expression of Vascular Endothelial Growth Factor (VEGF) (Funamoto et al., 2000; Jove et al., 2001) and promoting tumor angiogenesis through the up-regulation of VEGF .
In addition to the constitutive activation of Stat3 commonly detected in prostate cancer cells, alterations in the p53 tumor suppressor gene is also frequently detected in human prostate carcinoma (Navone et al., 1993; Meyers et al., 1998) . P53 functions as a tumor suppressor and two of the major activities of p53 includes its ability to transcriptionally activate downstream genes that induce G1 cell growth arrest and apoptosis, particularly upon DNA damage (Kuerbitz et al., 1992; Lowe et al., 1993) . At present, it is known whether wt p53 modulates the Stat3 activates. It is also not known whether constitutive activation of Stat3 selectively occurs in human prostate cancer that harbor inactivating mutations of the p53. In this study, we sought to explore the potentially functional relationship between p53 and Stat3 proteins in human prostate cancer cells.
Constitutive activation of Stat3 was reported in DU145 and Tsu human prostate cancer cell lines (Ni et al., 2000) . We ®rst examined the potential eect of reintroduction of wt p53 in DU145 prostate cancer cell lines, which express both constitutively active Stat3 and mutant p53 (Ni et al., 2000; Isaacs et al., 1991) . Cells were infected with control adenovirus (NCV), adenovirus wt p53 , of functionally inactivated p53 mutant, p53-175. p53-175 mutant contains single amino acid substitution at residue 175. Mutation at residue 175 is frequently occurred in prostate cancer. In cells infected with adenovirus wt p53, a dramatic reduction of phosphorylated Stat3 protein was observed (Figure 1a ). In contrast, in cells infected with NCV or adenovirus p53-175, the levels of phosphorylated Stat3 protein was not reduced ( Figure  1a) . These results suggest that reduction of phosphorylated Stat3 is speci®c mediated by the expression of wt p53. Expression of wt p53 did not cause reduction of phosphorylation-independent Stat3 and GAPDH proteins. However, only cells infected with adenovirus wt p53, p53 downstream targets, p21
WAF-1 and mdm2 proteins, were signi®cantly induced ( Figure 1a ). Since Stat3 is activated by phosphorylation on Tyr705, which leads to dimer formation and recognition of Stat3-speci®c DNA binding elements and activation of target gene transcription, we next examined whether wt p53 also reduces Stat3 DNA binding activity. Our results demonstrated that wt p53 inhibited constitutive Stat3 speci®c DNA binding activity in DU145 prostate cancer cells using an EMSA analysis (Figure 1b) . Wt p53 but not mutant p53 also induced signi®cant apoptosis in this cancer cell line (Figure 1c) . To exclude the possibility that infection of this cell line with adenovirus wt p53 may cause global reduction of phosphorylated proteins, we further examined distinct kinases in two other signal transduction pathways, AKT and ERK1/2. Expression of wt p53 did not cause a reduction of phosphorylated WRK1/2 protein ( Figure 1a ). In cells infected by NCV, adenovirus wt p53, and adenovirus p53-175, phosphorylated AKT levels were even increased ( Figure 1a) . Therefore, the inhibition of phosphorylated Stat3 caused by wt p53 seems to be speci®c.
We next examined the inhibition of Stat3 phosphorylation by wt p53 in a Tsu prostate cancer cell line, which also expresses constitutively active Stat3 and mutant p53 (Ni et al., 2000; Isaacs et al., 1991) . Similar reduction of phosphorylated Stat3 (Figure 2a ), inhibition of Stat3 DNA binding activity ( Figure 2b ) and induction of apoptosis ( Figure 2c ) by wt p53 was also observed in Tsu cells that were infected with Figure 1 The eect of Stat3 phosphorylation and induction of apoptosis by wt p53 in DU145 human prostate cancer cells. DU145 cancer cells were infected with NCV, adenovirus wt p53 or adenovirus p53-175 at multiplicity of infection (MOI) of 100 plaqueforming units (pfu)/ml. (a) Twenty-four hours after infection, 100 mg of total proteins from the cell lysates were subjected to SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blotted with phospho-speci®c Stat3 (Tyr-705; Cell Signaling Tech., Beverly, MA, USA), phospho-independent Stat3, phospho-speci®c AKT (Ser-473; Cell Signaling Tech.), phospho-speci®c ERK (Thr-202/Tyr-204; Cell Signaling Tech.), p53 (Clone 1801; generously provided by Arnold Levine), mdm2 (Clones 2A10 and 4B11; generously provided by Arnold Levine), p21
WAF-1 (Oncogene Research, Cambridge, MA, USA), or GAPDH (Chemicon International, Inc., Temecula, CA, USA) antibody. (b) Eect of wt p53 on Stat3 speci®c DNA binding activity. DU145 prostate cancer cells were either un-infected or infected with the NCV or adenovirus wt p53 at a MOI of 100 pfu per cell. Twenty-four hours after infection, cell extracts were prepared and analysed for DNA binding activity using radiolabeled double-strand Stat3 consensus binding motif as previously described (Lin et al., 2002) . (c) Cells were stained with propidium iodide (PI) and examined for apoptosis with sub-G1 pro®le analysis using a FACScan¯ow cytometer. The results are given as the average and standard deviations of Log PI from three independent experiments adenovirus wt p53 but not with adenovirus p53-175 or NCV. Only cells infected with adenovirus wt p53, p53 downstream targets, p21
WAF-1 and mdm2 proteins, were signi®cantly induced (Figure 2a) . Expression of wt p53 did no decrease phosphorylation-independent Stat3 protein in both DU145 and Tsu prostate cancer cell lines (Figures 1a and 2a) suggesting that the decreased levels of phosphorylated Stat3 is not due to the degradation or reduction of total Stat3 protein.
Expression of wt p53 even up-regulated the levels of phosphorylated AKT and phosphorylated ERK1/2 proteins in Tsu prostate cancer cells (Figure 2a) . Therefore, these results demonstrate that wt p53 speci®cally inhibits Stat3 tyrosine phosphorylation and Stat3 DNA binding activity in both prostate cancer cells expressing constitutively active Stat3.
We next examine whether p53-targeted protein, p21 is involved in the inhibition of Stat3 phosphorylation. DU145 prostate cancer cells were infected with adenovirus wt p53 or wt adenovirus p21 WAF-1 (Hall et al., 2000) . Only cells infected with adenovirus wt p53, mdm2 protein was signi®cantly induced (Figure 3a) . Considerable amount of p21 protein was expressed in cells infected with adenovirus wt p21
WAF-1 (Figure 3a) . However, expression of high levels of p21 WAF-1 in cells infected with adenovirus wt p21 WAF-1 , did not have inhibitory eect on Stat3 tyrosine phosphorylation (Figure 3a ) whereas expression of wt p53 reduced endogenous Stat3 phosphorylation (Figure 3a) . Expression of wt p53 but not wt p21 WAF-1 also induced dramatic apoptosis (Figure 3b ). Therefore, these results suggest that the p53 downstream target, p21
WAF-1 , is very unlikely to mediate the inhibition of Stat3 phosphorylation or induction of apoptosis in these cancer cells. Src, Janus kinase 2(JAK2) and epidermal growth factor receptor (EGFR) are upstream activators of Stat3 (Sartor et al., 1997; Bromberg et al., 1998; Turkson et al., 1998; Garcia et al., 2001) . Wt p53 or an un-identi®ed p53 downstream target may inhibit upstream activator(s) of Stat3 to phosphorylate Stat3 and subsequently result in decreased phosphorylation of Stat3. we further examine whether wt p53 inhibits phosphorylation of EGFR of Src. Expression of wt p53 in either DU145 or Tsu cancer cells did not have any signi®cant eect on EGFR or Src phosphorylation (Figure 3c ). These results suggest that reduction of Stat3 phosphorylation is very unlikely the downstream consequence of the inhibition of EGFR or Src by wt p53 at least in DU145 and Tsu prostate cancer cell lines. Further Twenty-eight hours after infection, cell extracts were prepared and analysed for DNA binding activity using radiolabeled double-stranded Stat3 consensus binding motif as previously described (Lin et al., 2002) . (c) Cells were stained with PI and examined for apoptosis with sub-G1 pro®le analysing using a FACScan¯ow cytometer. The results are given as the average and standard deviations of Log PI from three independent experiments p53 inhibits Stat3 in prostate cancer cells J Lin et al DU145 cells do not express detectable phosphorylated JAK2 whereas Tsu cells express phosphorylated JAK2 (data not shown). Therefore, it is also unlikely that reduction of Stat3 is due to inhibition of JAK2 by wt p53 at least in DU145 prostate cancer cell line. Wt p53 inhibits Stat3 phosphorylation at tyrosine residue 705 and inhibits Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cells. The tyrosine phosphorylation of Stat3 at residue 705 and DNA binding activity is required and essential for the activation of Stat3 activities (Zhong et al., 1994) . These results suggest that anti-proliferative activities of wt l53 may be not compatible with the expression of constitutive activation of Stat3 in prostate cancer cells. Accordingly, constitutive activation of Stat3 may selectively occur in prostate cancer cells containing inactive mutations of p53. In fact, both DU145 and Tsu prostate cancer cells express mutant or null p53 (Isaacs et al., 1991) . We further evaluated the published reports of the status of Stat3 (Garcia et al., 1997; Huang et al., 2000; Ni et al., 2000) and p53 (Bartek et al., 1990; Isaacs et al., 1991; Yaginuma and Westphal, 1992 ; Brown et al., 1993; Elstner et al., 1995; Tagliaferri et al., 1996; Jacobberger et al., 1999) in prostate, breast, and ovarian cancer cell lines. We found that all cancer cell lines that express constitutively active Stat3 only express mutant or null p53 (Table 1 ). In contrast, cancer or immortalized cell lines, which do not express constitutively active Stat3, express either wt p53 or mutant p53 (Table 1) . A possibility is that Stat3 may be normally suppressed by wt p53 in normal cells of cancer cells expressing endogenous wt p53. Inactivation of p53 by mutation may be involved in activating Stat3. However, MDA-MB-453 breast cancer cells that harbor mutant p53 (Katayose et al., 1995) , do not express constitutively active Stat3 (Garcia et al., 2001 ) would argue against this possibility (Table 1) . Rather, Stat3 is most likely activated by upstream activators such as Src, JAK, and EGFR in cancer cells (Sartor et al., 1997; Bromberg et al., 1998; Turkson et al., 1998; Garcia et al., 2001) . Therefore, at least from these cancer cell lines, there is a clear correlation that constitutive activation of Stat3 selectively occurs in cells harboring p53 mutation or deletion. These results further support out hypothesis that (prostate) cancer cells expressing constitutively Figure 3 The eect of Stat3 phosphorylation and induction of apoptosis by wt p53 or p21 WAF-1 in prostate cancer cells. DU145 prostate cancer cells were infected with MOI of 100 pfu/ml of NCV, adenovirus wt p53 or adenovirus wt p21 . (a) Twenty-four hours after infection, phosphorylated Stat3, phospho-independent Stat3, phosphorylated ERK p53, mdm2 and p21 WAF-1 protein were analysed by Western blotting as described in the legend to Figure 1. (b) Cells were also stained with PI and examined for apoptosis with sub-G1 pro®le analysis using a FACScan¯ow cytometer. The results are given as the average and standard deviations of Log PI from three independent experiments. (c) Eect of phosphorylated Src and EGFR by wt p53 in DU145 and Tsu prostate cancer cells. DU145 or Tsu prostate cancer cells were infected with MOI of 100 or 200 pfu/ml of NCV or adenovirus wt p53 respectively. 24 ± 28 hours after infection, 100 mg of total proteins from the cell lysates were analysed with phospho-speci®c EGFR (Tyr 1068; Cell Signaling Tech., Beverly, MA, USA) or phosphorylation-independent antibody. To analyse the phosphorylated Src protein, 800 mg of proteins from the cell lysates were immunoprecipitated with anti-Src antibody (Upstate Biotechnology) and analysed with phospho-tyrosine speci®c antibody (BD Transduction Laboratory) by Western blotting active Stat3 may need to further mutate p53 to escape p53-dependent apoptosis and be able to continue tumor progression. Consistently, DU145 and Tsu prostate cancer cell lines (Figures 1 and 2 ) and MDA-MB-468 and SK-BR-3 breast cancer cells (Lin et al., 2002) that express constitutively active Stat3 are very sensitive to p53-dependent apoptosis.
Wt p53 or a p53 targeted gene product may directly or indirectly inhibit Stat3 phosphorylation and subsequently inhibits Stat3 DNA binding activity. One possible mechanism is that a tyrosine phosphatase dephosphorylating Stat3 at residue Tyr705 is induced by wt p53. Alternatively, wt p53 or a p53 targeted gene product may inhibit upstream activator(s) of Stat3 such as Src, JAK2, or EGFR to phosphorylate and active Stat3. however, our results suggest that inhibition if EGFR or Src is very unlikely an upstream event that causes the reduction of Stat3 by wt p53 at least in both DU145 and Tsu prostate cancer cell lines (Figure 3c) . Further, one of the p53 downstream targets, p21 WAF-1 , did not aect Stat3 phosphorylation, although it may still aect Stat3 activity (Coqueret and Gascan, 2000) . Therefore, other p53-downstream gene product(s) such as tyrosine phosphatase may be involved in the inhibition of Stat3 tyrosine phosphorylation. Interestingly, wt p53 can also inhibit Stat3 activation medicated by IL-6 in human hepatoma Hep3B cell line (Rayanade et al., 1998) . Fritsche et al. (1998) have also made interesting observation that wt p53 can suppress cytokine-induced Stat4-medidated activation of transcription. In that study, the authors demonstrated that wt p53 does not interfere with either upstream phosphorylation events or Stat5 DNA binding but rather transcriptional activation mediated by Stat5. In this study, we also showed that wt p53 does not interfere with upstream phosphorylation events such as Src, EGFR which is consistent with their study. However, we showed that wt p53 inhibited both tyrosine phosphorylation and DNA binding activity of Stat3 (Figures 1 and 2) . Therefore, there seems to be certain similarity and dierences between the inhibition of constitutively active Stat3 in prostate cancer cells and the cytokine-induced Stat5 (Fritsche et al., 1998) by wt p53. Taken together, these studies not only support our results that wt p53 can inhibit Stat3 but further suggest that wt p53 also suppresses Stat5 pathway activated by cytokines.
Over-expression of oncogene products including ras and c-myc, has been shown to stabilize p53 protein and active p53 activities (Palmero et al., 1998; Zindy et al., 1998) . It may be possible that constitutively activated Stat3 oncogene product (by upstream regulators) may function similarly as ras or c-myc that cause the activation of p53 and subsequent induction of growth arrest/apoptosis. P53 may then serve as a safeguard against oncogenic deregulation of Stat3. Only cancer cells that further mutate p53 or inactivate the p53 pathway may be able to escape p53-dependent apoptosis/growth arrest and be able to continue tumor progression. Therefore, constitutive activation of Stat3 may be selectively present in cancer cells that harbor inactivating mutation or deletion of the p53 gene, which may enable cancer cells to escape inhibition by wt p53 pathway particularly after DNA damage. This hypothesis is partially supported by the published reports of the status of Stat3 and p53 in prostate (DU145 and Tsu), breast (MDA-MB-468 and SK-BR-3) and ovarian (MDAH 2774, SKOV-3 and Caov-3) cancer cell lines which all these cancer cell lines expressing both constitutively active Stat3 and mutant or null p53 (Table 1 ). In contrast, LNCaP, MCF-7 and A2780 cancer cells that do not express constitutively active Stat3 still retain endogenous wt p53 (Table 1) . However, it is also possible that constitutive activation of Stat3 and inactivation of p53 tumor suppressor are two independent events leading to tumor progression. For example, certain mutations of p53 could gain new functions that are not shared by wt p53 (Dittmer et al., 1993) . The gain of function of p53 mutation may gain growth advantage of tumor cells and may be an independent step with Stat3 activation. However, if constitutive activation of Stat3 and inactivation of p53 (Figures 1 and 2) . Interestingly, apoptosis occurred in the presence of phosphorylated AKT and phosphorylated ERK1/2 whereas only phosphorylated Stat3 is down regulated (Figures 1  and 2 ). Similar reduction of phosphorylated Stat3 (but no reduction of phosphorylated AKT and ERK1/2) and induction of apoptosis by wt p53 were also observed in MAD-MB-468 and SK-BR-3 breast cancer cell line (Lin et al., 2002) that express constitutively active Stat3. AKT and possibly ERK1/2 and Stat3 are cell survival pathways that inhibits apoptosis (Xia et al., 1995; Datta et al., 1997; Catlett-Falcone et al., 1999; Shen et al., 2001) . It is unlikely that inhibition of AKT survival pathways by wt p53 is involved in p53-dependent apoptosis at least in DU145 and Tsu prostate cancer cells. However, suppression of AKT survival pathway by wt p53 may be involved in p53-dependent apoptosis in other cancer cells that express constitutively active AKT. It is also possible that in prostate cancer cells that express constitutively active Stat3, cells may be dependent on Stat3 for survival. These cells undergo dramatic apoptosis when Stat3 is inhibited by dominant-negative Stat3 (Niu et al., 1999 Burke et al., 2001) or by wt p53 (Figures 1 and  2) . Thus, these cancer cell lines (DU145 and Tsu) only contain mutant or null p53 that permit them to escape from p53-dependent apoptosis particularly after DNA damage. p53 may induce apoptosis through activation of downstream targets that involved in apoptosis or repression of targets that involved in anti-apoptosis (Murphy et al., 1996; Polyak et al., 1997) . Therefore, more experiments will be necessary to test whether inhibition of constitutively active Stat3 may be one of the many pathways that are involved in p53-dependent apoptosis in cancer cells expressing constitutively active Stat3. However, in cancer or normal cells that do not express constitutively active Stat3, p53 may induce apoptosis through dierent pathways that are independent of the inhibition of Stat3.
In summary, we showed that wt p53 signi®cantly reduces Stat3 tyrosine phosphorylation and inhibits Stat3 DNA binding activity in prostate cancer cell lines that express both constitutively active Stat3 and mutant p53 protein. Our results identi®ed a novel p53-dependent but p21 independent cellular process in these prostate cancer cells that negatively regulated Stat3 tyrosine phosphorylation and DNA binding activity.
